• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

  • in Oncology
  • — 10 Dec, 2007
Live Report from ASH:<br />Oblimersen Extends Survival in Chronic Lymphocytic Leukemia
AudioMedica News
Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia
Live Report from ASH:<br />Oblimersen Extends Survival in Chronic Lymphocytic Leukemia
00:00 /
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-386"/>
Susan O’Brien
Susan O’Brien

SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.

Live Report from ASH:<br />Oblimersen Extends Survival in Chronic Lymphocytic Leukemia



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/071209_susan_o_brien.mp3]

You may also like...

  • Metastatic renal cell carcinoma: biomarkers to guide future therapy Metastatic renal cell carcinoma: biomarkers to guide future therapy 25 Feb, 2014
  • PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression 31 Oct, 2018
  • Rosalind Perrin MD ‘Rescanning’ Optimizes Pencil Beam Proton Delivery to Moving Lung Tumor 12 May, 2015
  • Stefan Aibi and Irene Wapnir Local or regional breast cancer recurrences mandate adjuvant chemotherapy 11 Dec, 2012

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Live Report from ASH:
    Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML
  • Next story Live Report from ASH:
    Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • New Front Line Standard for Older Patients with…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Microbiome Diversity Key To Survival After…
    • Venetoclax Pro-Apoptotic Therapy Benefits Older…
  • Home
  • Oncology
  • Live Report from ASH:
    Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

© COPYRIGHT 2020 AUDIOMEDICA.COM.